Levi & Korsinsky notifies investors that it has commenced an investigation into Sanara MedTech Inc. (NASDAQ: SMTI) concerning potential violations of the federal securities laws.
On November 11, 2025, Sanara announced that it would be “discontinuing operations of [its Tissue Health Plus (“THP”) program] to improve its operating efficiency and reallocate resources to its core surgical business.” The following day, before market hours, Sanara released its third quarter 2025 financial results, reporting that its “net loss from discontinued operations . . . was $31.2 million,” which “includes a noncash asset impairment charge of $26.5 million . . . related to the discontinued operations of THP.” Following this news, Sanara’s stock price fell over 24% on November 12, 2025.
If you suffered a loss on your Sanara MedTech Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





